Showing 1 - 5 results of 5 for search 'R. Celis', query time: 0.02s Refine Results
  1. 1
    DISTRIBUCION SUPERFICIAL DE ALGUNOS PARAMETROS HIDROLOGICOS FISICOS Y QUIMICOS EN EL ESTERO DE PUNTA BANDA, B. C. EN PRIMAVERA Y VERANO.

    DISTRIBUCION SUPERFICIAL DE ALGUNOS PARAMETROS HIDROLOGICOS FISICOS Y QUIMICOS EN EL ESTERO DE PUNTA BANDA, B. C. EN PRIMAVERA Y VERANO. by R. Celis-Ceseña, S. Alvarez-Borrego

    Published 1975-03-01
    Get full text
    Article
  2. 2
    Formulaciones basadas en organoarcilla para reducir el im­pacto producido por el uso de herbicidas en suelos de olivar Organoclay-based formulations to reduce the environmental impact caused by herbicides commonly applied to olive groves

    Formulaciones basadas en organoarcilla para reducir el im­pacto producido por el uso de herbicidas en suelos de olivar Organoclay-based formulations to reduce the environmental imp... by C. Trigo, R. Celis, G. Facenda, J. Cornejo

    Published 2010-01-01
    Get full text
    Article
  3. 3
    Short-, mid-, and long-term complications after multisystem inflammatory syndrome in children over a 24-month follow-up period in a hospital in Lima-Peru, 2020–2022

    Short-, mid-, and long-term complications after multisystem inflammatory syndrome in children over a 24-month follow-up period in a hospital in Lima-Peru, 2020–2022 by Giancarlo Alvarado-Gamarra, Giancarlo Alvarado-Gamarra, Giancarlo Alvarado-Gamarra, Matilde Estupiñan-Vigil, Raquel Garcés-Ghilardi, Jesús Domínguez-Rojas, Olguita del Águila, Katherine Alcalá-Marcos, Rafael Márquez Llanos, Lucie Ecker, Carlos R. Celis, Carlos Alva-Diaz, Carlos Alva-Diaz, Claudio F. Lanata, Claudio F. Lanata, Claudio F. Lanata

    Published 2023-11-01
    Get full text
    Article
  4. 4
    Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

    Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] by Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

    Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study by Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels

    Published 2022-08-01
    Get full text
    Article

Search Tools: